Labiotech.eu

News and Trends 24 Jan 2015

Important Bilateral Academic Agreement for the Future of iPS Cell Therapy

The UK Cell Therapy programme Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, has signed a patent licence agreement with iPS Academia Japan. It represents a pivotal step in the development of the UK’s GMP induced pluripotent stem (iPS) cell bank. Under the […]

January 24, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 23 Jan 2015

A glimpse of the future: the revolution of bionic eyes

Six months after the surgery, the first Spanish with a bionic eye has gone from the total darkness to discern shapes and distances thanks to the technology developed by Second Sight Medical Products. With the MedTech field moving forward so fast, a new generation of devices meant to restore the sense of vision is about […]

January 23, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 22 Jan 2015

Novabiotics Tackles Antibiotic Resistance by Raising €6,5M Euros

NovaBiotics Ltd has raised €6,5M for priority clinical stage first-in-class antimicrobial therapeutics assets. The private placement with Woodford Investment Management LLP was arranged by Shore Capital as financial adviser and broker to the company. NovaBiotics is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. NovaBiotics has spent more than 10 […]

January 22, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 21 Jan 2015

Review: The CRISPR’s Therapeutical revolution

Six years ago, a new sophisticated prokaryotic defense system, was identified in the structure complex CRISPR-Cas9 (CRISPR, clustered regularly interspaced short palindromic repeats; Cas, CRISPR associated nuclease). “Resistance is acquired by incorporating short stretches of invading DNA sequences in genomic CRISPR loci ” Brouns, S. J. J., et al. (2008). The CRISPR repeat sequence has […]

January 21, 2015 - 4 minutesmins - By Cédric Brock

News and Trends 20 Jan 2015

Will Microalgaes solve the Rare Earth conflict?

The extraction of rare earths is a very expensive process, having dramatic consequences for the planet (degradation, impacts on water quality, etc.). Currently, China controls 95% of the World production of these minerals widely used in the field of new technologies and electronics. The development of new methods of sustainable recycling from waste and environmentally friendly is […]

January 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 17 Jan 2015

Qiagen, the new giant in next-gen sequencing tools?

Yet again, a new acquisition in this beginning of 2015. Enzymatics, the Boston-area based Biotech company and leading provider of enzymes for Next-gen sequencing, has been acquired by Qiagen for a non-disclosed amount. The amount must be pretty high since Enzymatics’ enzymes are used in 80% of all NGS reactions and the company counts over 150 employees. […]

January 17, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 13 Jan 2015

Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

2015 starts in a rush for the Biotech industry. Swiss Pharma-giant Roche just announced paying $1B to acquire 56% percent of leading molecular information and genomic analysis Biotech company Foundation Medicine. Foundation Medicine is a leading Biotech company in the field of molecular information and genomic analysis. It uses next-gen sequencing technology and solid bioinformatic analysis […]

January 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 9 Jan 2015

Will Nestlé lead the promising microbiome industry?

Nestlé is one of the food giants in the World. Last Tuesday, it made a huge step in the microbiome industry by investing $65M in Boston-based Seres Health, one of the most advanced Biotech start-ups in the field. Will Nestlé take control of the promising microbiome industry? Seres Health is a leading microbiome therapeutics platform company developing […]

January 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 8 Jan 2015

Nanobiotix on its way to change the paradigm in cancer therapy

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell. The following video is showing how this disruptive technology is acting […]

January 8, 2015 - 4 minutesmins - By Joachim Eeckhout

News and Trends 6 Jan 2015

The largest VC investment in a single Biotech company has just been made

Wow, 2015 starts in a rush for the biotech industry. Moderna Therapeutics, Boston-based company led by French co-founding CEO Stephan Bancel just raised $450M (€380M) in VC investment. According to The Wall Street Journal, it is the largest VC-Investment ever made in a Biotech company. Moderna was founded only in 2011 and is an awesome company […]

January 6, 2015 - 1 minutemin - By Philip Hemme

News and Trends 22 Dec 2014

Biotech’s crowdfunding: is France top of the class?

No need to present the crowdfunding again! We hear about it every day through Kickstarter’s projects or other platforms that abound on the web. But what about biotech’s crowdfunding? Through many French entrepreneur’s interviews who are engaged in crowdfunding’s campaigns, I tried to make my own idea about this new financing tool. And one thing […]

December 22, 2014 - 5 minutesmins - By Joachim Eeckhout

News and Trends 20 Dec 2014

French Biotech Start-up Adocia signs Massive €464M Diabetes Deal with Eli Lilly

The French biotechnology company Adocia entered into an alliance with the US Eli Lilly on the co-development of an ultra-fast insulin to treat type 1 and type 2 diabetes. This insuline, called BioChaperone Lispro, has been developed through Adocia’s technology BioChaperone, is currently in Phase Ib clinical study. Under this global license agreement with Adocia, Eli Lilly […]

December 20, 2014 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us